Case report: Dupilumab leads to an increased chance of head and neck Staphylococcus aureus infection in atopic dermatitis patients

Dupilumab was the first biological medication licensed to treat atopic dermatitis (AD), and it has shown remarkable effectiveness and safety in the treatment of moderate-to-severe atopic dermatitis. There are limited drug-related adverse events associated with dupilumab in atopic dermatitis (AD) tre...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Min, Gao, Kai, Ali, Kamran, Shan, Jinpeng, Qiu, YunMi, Xie, Tianci, Yu, Yiling, Wu, Liming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10031056/
https://www.ncbi.nlm.nih.gov/pubmed/36968828
http://dx.doi.org/10.3389/fmed.2023.1027589

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10031056/
https://www.ncbi.nlm.nih.gov/pubmed/36968828
http://dx.doi.org/10.3389/fmed.2023.1027589

Ejemplares similares